Concepts (157)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myeloid Cells | 2 | 2022 | 269 | 0.920 |
Why?
|
| Immunotherapy | 9 | 2023 | 3341 | 0.800 |
Why?
|
| Glioblastoma | 2 | 2023 | 1797 | 0.760 |
Why?
|
| CTLA-4 Antigen | 4 | 2020 | 657 | 0.760 |
Why?
|
| 5'-Nucleotidase | 1 | 2019 | 61 | 0.710 |
Why?
|
| Programmed Cell Death 1 Receptor | 4 | 2020 | 1048 | 0.620 |
Why?
|
| Molecular Targeted Therapy | 2 | 2019 | 2330 | 0.610 |
Why?
|
| Ipilimumab | 2 | 2021 | 710 | 0.610 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2018 | 245 | 0.580 |
Why?
|
| Genetic Markers | 1 | 2017 | 974 | 0.490 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2018 | 673 | 0.490 |
Why?
|
| Immunomodulation | 1 | 2016 | 242 | 0.490 |
Why?
|
| Single-Cell Analysis | 1 | 2018 | 470 | 0.490 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2023 | 2341 | 0.400 |
Why?
|
| Neoplasms | 6 | 2023 | 15193 | 0.390 |
Why?
|
| Antineoplastic Agents, Immunological | 3 | 2020 | 1249 | 0.380 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2009 | 32 | 0.340 |
Why?
|
| Respiratory Mucosa | 1 | 2009 | 206 | 0.310 |
Why?
|
| Antibodies, Monoclonal | 2 | 2020 | 4367 | 0.300 |
Why?
|
| B7-H1 Antigen | 4 | 2023 | 1022 | 0.290 |
Why?
|
| Interleukins | 1 | 2009 | 325 | 0.290 |
Why?
|
| Tretinoin | 1 | 2009 | 623 | 0.280 |
Why?
|
| Tumor Microenvironment | 5 | 2022 | 2864 | 0.250 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2022 | 2326 | 0.250 |
Why?
|
| Macrophages | 2 | 2022 | 1304 | 0.250 |
Why?
|
| Biomarkers | 3 | 2022 | 5047 | 0.240 |
Why?
|
| Mice, Inbred C57BL | 5 | 2019 | 6942 | 0.230 |
Why?
|
| Kidney Neoplasms | 3 | 2022 | 3022 | 0.230 |
Why?
|
| Urinary Tract | 1 | 2023 | 82 | 0.220 |
Why?
|
| Brain Neoplasms | 1 | 2019 | 4849 | 0.220 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2023 | 113 | 0.210 |
Why?
|
| Histone Demethylases | 1 | 2023 | 144 | 0.210 |
Why?
|
| Prostatic Neoplasms | 2 | 2016 | 5767 | 0.210 |
Why?
|
| Asthma | 1 | 2009 | 871 | 0.190 |
Why?
|
| Chemokine CXCL13 | 1 | 2020 | 21 | 0.190 |
Why?
|
| Urogenital Neoplasms | 1 | 2021 | 108 | 0.190 |
Why?
|
| Cell Dedifferentiation | 1 | 2020 | 96 | 0.180 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2020 | 1763 | 0.180 |
Why?
|
| Animals | 10 | 2023 | 59536 | 0.180 |
Why?
|
| Humans | 24 | 2023 | 261506 | 0.170 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 1 | 2019 | 76 | 0.170 |
Why?
|
| Mice | 7 | 2023 | 34495 | 0.170 |
Why?
|
| GPI-Linked Proteins | 1 | 2019 | 223 | 0.170 |
Why?
|
| Urothelium | 1 | 2020 | 254 | 0.170 |
Why?
|
| Monocytes | 1 | 2022 | 788 | 0.160 |
Why?
|
| Cell Line, Tumor | 5 | 2019 | 14551 | 0.150 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2023 | 716 | 0.150 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2019 | 992 | 0.150 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2022 | 1033 | 0.140 |
Why?
|
| Immunity | 2 | 2016 | 342 | 0.140 |
Why?
|
| Antineoplastic Agents | 2 | 2016 | 14289 | 0.140 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 598 | 0.140 |
Why?
|
| Academies and Institutes | 1 | 2016 | 95 | 0.140 |
Why?
|
| Research Report | 1 | 2016 | 144 | 0.130 |
Why?
|
| Neoplasms, Experimental | 1 | 2018 | 750 | 0.130 |
Why?
|
| Congresses as Topic | 1 | 2016 | 298 | 0.120 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2019 | 1586 | 0.120 |
Why?
|
| Mice, Transgenic | 2 | 2019 | 4143 | 0.120 |
Why?
|
| Phenotype | 2 | 2023 | 6295 | 0.120 |
Why?
|
| Transcription Factors | 2 | 2020 | 5270 | 0.120 |
Why?
|
| Piperidines | 1 | 2018 | 1035 | 0.110 |
Why?
|
| Receptors, Interleukin-8B | 1 | 2012 | 56 | 0.110 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2014 | 270 | 0.110 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2016 | 582 | 0.110 |
Why?
|
| Indoles | 1 | 2018 | 1009 | 0.110 |
Why?
|
| Immune Tolerance | 1 | 2014 | 403 | 0.110 |
Why?
|
| Gene Expression Profiling | 2 | 2023 | 5159 | 0.110 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 7222 | 0.110 |
Why?
|
| Enzyme Inhibitors | 1 | 2018 | 1879 | 0.100 |
Why?
|
| Clinical Trials as Topic | 2 | 2023 | 3719 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 3251 | 0.090 |
Why?
|
| Homeodomain Proteins | 1 | 2014 | 1143 | 0.080 |
Why?
|
| Retinal Dehydrogenase | 1 | 2009 | 91 | 0.080 |
Why?
|
| Carcinoma | 1 | 2020 | 2578 | 0.080 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2009 | 212 | 0.080 |
Why?
|
| Algorithms | 1 | 2019 | 3890 | 0.080 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2009 | 254 | 0.080 |
Why?
|
| Th2 Cells | 1 | 2009 | 257 | 0.080 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2009 | 548 | 0.080 |
Why?
|
| Elastin | 1 | 2007 | 49 | 0.080 |
Why?
|
| Allergens | 1 | 2009 | 247 | 0.070 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 4821 | 0.070 |
Why?
|
| Biomarkers, Tumor | 3 | 2020 | 10331 | 0.070 |
Why?
|
| Emphysema | 1 | 2007 | 87 | 0.070 |
Why?
|
| Autoimmunity | 1 | 2007 | 263 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2022 | 4557 | 0.060 |
Why?
|
| Pulmonary Alveoli | 1 | 2006 | 208 | 0.060 |
Why?
|
| Cisplatin | 2 | 2023 | 2432 | 0.060 |
Why?
|
| Oncogene Proteins | 1 | 2006 | 354 | 0.060 |
Why?
|
| Lymphocyte Activation | 1 | 2009 | 1688 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2019 | 8873 | 0.060 |
Why?
|
| Male | 9 | 2022 | 123000 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 7702 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 3639 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2020 | 10035 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2021 | 32848 | 0.050 |
Why?
|
| Smoking | 2 | 2012 | 2440 | 0.050 |
Why?
|
| Neoplasm Metastasis | 3 | 2021 | 5112 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2021 | 15862 | 0.050 |
Why?
|
| Proteomics | 1 | 2009 | 1380 | 0.050 |
Why?
|
| MicroRNAs | 1 | 2014 | 2947 | 0.050 |
Why?
|
| Lung Neoplasms | 2 | 2014 | 11538 | 0.050 |
Why?
|
| Endpoint Determination | 1 | 2021 | 176 | 0.050 |
Why?
|
| Mutation | 1 | 2020 | 15179 | 0.050 |
Why?
|
| Anilides | 1 | 2022 | 268 | 0.050 |
Why?
|
| Cytokines | 1 | 2009 | 2809 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2009 | 5710 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2021 | 403 | 0.040 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 8865 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2006 | 1491 | 0.040 |
Why?
|
| Drug Discovery | 1 | 2021 | 324 | 0.040 |
Why?
|
| Forecasting | 1 | 2021 | 694 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2009 | 4078 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 7548 | 0.040 |
Why?
|
| Deoxycytidine | 1 | 2023 | 1353 | 0.040 |
Why?
|
| Aged | 5 | 2021 | 70117 | 0.040 |
Why?
|
| California | 1 | 2016 | 208 | 0.030 |
Why?
|
| Comprehension | 1 | 2016 | 120 | 0.030 |
Why?
|
| Middle Aged | 5 | 2021 | 86204 | 0.030 |
Why?
|
| Pyridines | 1 | 2022 | 1244 | 0.030 |
Why?
|
| Cancer Vaccines | 1 | 2020 | 697 | 0.030 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2022 | 1248 | 0.030 |
Why?
|
| Databases as Topic | 1 | 2014 | 133 | 0.030 |
Why?
|
| Adult | 4 | 2021 | 77950 | 0.030 |
Why?
|
| Retrospective Studies | 3 | 2021 | 37905 | 0.030 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2014 | 159 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2012 | 7789 | 0.030 |
Why?
|
| Gene Targeting | 1 | 2014 | 292 | 0.030 |
Why?
|
| Female | 5 | 2022 | 141928 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2016 | 669 | 0.030 |
Why?
|
| Hospitalization | 1 | 2021 | 2083 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 29902 | 0.020 |
Why?
|
| Sarcoma | 1 | 2020 | 1725 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2012 | 1077 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2021 | 9180 | 0.020 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2014 | 973 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2021 | 9244 | 0.020 |
Why?
|
| Models, Biological | 1 | 2014 | 3254 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 13658 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 3981 | 0.020 |
Why?
|
| Pulmonary Emphysema | 1 | 2006 | 145 | 0.020 |
Why?
|
| Risk Factors | 1 | 2020 | 17523 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2012 | 2669 | 0.010 |
Why?
|
| Fetus | 1 | 2006 | 601 | 0.010 |
Why?
|
| Melanoma | 1 | 2019 | 5317 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2014 | 7226 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2006 | 1338 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2019 | 11965 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2007 | 1294 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2006 | 1450 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2006 | 2074 | 0.010 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2007 | 1021 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 5319 | 0.010 |
Why?
|
| Lung | 1 | 2007 | 3151 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2006 | 6150 | 0.010 |
Why?
|
| Prognosis | 1 | 2012 | 21713 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2007 | 3869 | 0.010 |
Why?
|